Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study

American Journal of Ophthalmology
Kun LiuPHOENIX Study Group

Abstract

Age-related macular degeneration (AMD) can cause irreversible vision loss leading to blindness. We aim to evaluate the efficacy and safety of intravitreal injections of 0.5 mg conbercept, a new anti-vascular endothelial growth factor (anti-VEGF) drug, for treatment of AMD on a schedule more manageable for patients. A prospective, double-masked, multicenter, sham-controlled, phase III randomized trial. Patients: Patients with choroidal neovascularization (CNV) secondary to AMD were enrolled and randomized to the conbercept group or the sham control group. The conbercept group received intravitreal injections of conbercept (0.5 mg) once monthly for the first 3 months, then once quarterly until month 12 (3 + Q3M). The sham group received first 3 monthly sham injections and then 3 monthly injections of conbercept (0.5 mg) followed by quarterly administrations until month 12. The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA) at month 3. A total of 114 patients (91.9%) from 9 sites in China completed the 12-month study. At the 3-month primary endpoint, the mean changes in BCVA from baseline were +9.20 letters in the conbercept group and +2.02 letters in the sham group, respectively (P < .001). ...Continue Reading

Citations

Jun 11, 2019·Expert Opinion on Biological Therapy·Lorenzo Ferro DesideriMassimo Nicolò
Jul 13, 2019·Expert Opinion on Pharmacotherapy·Hasenin Al-KhersanPravin U Dugel
Nov 22, 2019·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Peipei WuPing Lin
Jan 10, 2020·Therapeutic Delivery·Georgios D Panos
Mar 25, 2020·Current Opinion in Ophthalmology·Michael J AmmarCarl D Regillo
Jun 2, 2020·Expert Opinion on Investigational Drugs·Lorenzo Ferro DesideriMassimo Nicolò
Jul 8, 2020·Current Eye Research·Huan LiuXiao-Rong Zhang
Jul 3, 2020·International Journal of Molecular Sciences·Olivia RastoinMaeva Dufies
Jun 9, 2020·Asia-Pacific Journal of Ophthalmology·Anindya SamantaJay Chhablani
Apr 29, 2020·Current Drug Targets·Claudio Campa
Dec 30, 2020·International Journal of Molecular Sciences·Emilie Grarup JensenThomas J Corydon
Jan 5, 2021·World Journal of Clinical Cases·Li JiangHui-Qin Yang
Jan 29, 2021·International Journal of Molecular Sciences·Arunbalaji PugazhendhiBalamurali Ambati
Feb 12, 2021·Frontiers in Cell and Developmental Biology·Majda Hadziahmetovic, Goldis Malek
Mar 12, 2021·Expert Opinion on Drug Delivery·Puneet Sharma, Sachin Mittal
Aug 11, 2021·Eye·Matias IglickiDinah Zur
Sep 4, 2020·Current Drug Safety·Tobias P H NissenKristian Aasbjerg
Oct 3, 2021·International Journal of Retina and Vitreous·Sruthi Arepalli, Peter K Kaiser
Oct 17, 2021·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Mariacristina ParravanoGianni Virgili
Nov 2, 2021·Advances in Therapy·Dionysis D BalatsoukasFotis Topouzis
Jul 3, 2021·Breastfeeding Medicine : the Official Journal of the Academy of Breastfeeding Medicine·Zheyi ShaoJianqiao Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.